Enrollment

BUD assessment and recruitment of eligible participants

BQ chewers with BUD in past year
n = 139

Eligible but refused or not contactable
n = 28

Eligible and agree to participant the trial
n = 111

Allocation

Randomize BQ chewers into 3 treatment groups

Follow-up 8 weeks

Allocated to Placebo
(*n* = 37)

Follow-up

Completed ≥2 weeks (*n* = 30)
Completed ≥4 weeks (*n* = 29)
Completed ≥6 weeks (*n* = 26)
Completed 8 weeks (*n* = 26)
BQ-CC assessment (*n* = 28)

Reasons for uncompleted 8 weeks follow-up

Failure to return (*n* = 2)
Refusing treatment (*n* = 7)
Insufficient response (*n* = 2)

Allocated to Escitalopram
(*n* = 38)

Follow-up

Completed ≥2 weeks (*n* = 35)
Completed ≥4 weeks (*n* = 34)
Completed ≥6 weeks (*n* = 34)
Completed 8 weeks (*n* = 34)
BQ-CC assessment (*n* = 35)

Reasons for uncompleted 8 weeks follow-up

Failure to return (*n* = 2)
Refusing treatment (*n* = 2)

Allocated to Moclobemide
(*n* = 36)

Follow-up

Completed ≥2 weeks (*n* = 31)
Completed ≥4 weeks (*n* = 31)
Completed ≥6 weeks (*n* = 31)
Completed 8 weeks (*n* = 31)
BQ-CC assessment (*n* = 31)

Reasons for uncompleted 8 weeks follow-up

Refusing treatment (*n* = 5)

Evaluation

Intention-to-treat analysis

Supplementary Fig 1. CONSORT Diagram for the evaluation of drug treatments for male chewers with betel-quid use disorder: a randomized placebo-controlled clinical trial. **Note**: BQ-CC denotes betel-quid chewing cessation.

Supplementary Table 1. Adverse events occurred during the 8-weeks of follow-up after drug treatments

Events	Placebo (n=37)		Escitalopram (n=38)		Moclobemide (n=36)		*P* value[a]
	No.	(%)	No.	(%)	No.	(%)	
Gastrointestinal event							
Constipation	0	0	1	2.6	0	0	1.000
Diarrhea	1	2.7	0	0	0	0	0.658
Nausea	0	0	1	2.6	0	0	1.000
Dry mouth	0	0	2	5.3	2	5.6	0.465
Psychiatric event							
Dizziness	0	0	0	0	5	13.9	0.003
Insomnia	1	2.7	0	0	2	5.6	0.210
Other systems							
Impotency	1	2.7	0	0	0	0	0.658

[a]*P* values were obtained from the Fisher's exact test.

Supplementary Table 2. The distribution and difference of clinical outcomes between before and after 8-weeks of drug treatments

Factors	Placebo			Escitalopram			Moclobemide		
	Before	**After**	P^a	**Before**	**After**	P^a	**Before**	**After**	P^a
	n = 35	*n* = 22		*n* = 36	*n* = 28		*n* = 34	*n* = 23	
Liver function									
GOT (IU/L)	34.9±18.9	27.1±8.9	0.079	37.6±21.3	31.1±18.9	0.213	40.1±33.0	31.5±17.7	0.256
GPT (IU/L)	39.5±29.6	32.9±22.8	0.372	33.6±25.4	31.0±18.8	0.651	42.0±31.7	33.7±22.8	0.286
Renal function									
BUN (mg/dL)	11.9±5.3	13.0±4.4	0.383	11.5±6.5	10.3±3.8	0.407	11.0±5.1	11.4±3.7	0.728
Creatinine (mg/dL)	0.9±0.2	0.9±0.2	0.949	1.0±0.5	0.9±0.2	0.330	1.0±0.2	1.0±0.3	0.360
Electrolytes									
Sodium (mmol/L)	138.9±3.8	138.7±2.8	0.891	138.5±3.4	139.4±2.2	0.239	136.7±3.5	137.7±2.7	0.252
Potassium (mmol/L)	4.2±0.4	4.1±0.4	0.184	5.0±5.7	4.0±0.4	0.357	4.0±0.5	4.1±0.4	0.607
Blood Tests									
WBC (10^3/ul)	8.1±2.2	1.3±2.5	0.256	8.7±2.5	7.9±1.7	0.161	8.5±3.6	8.6±2.6	0.965
Hemoglobin (g/dL)	15.1±1.9	15.2±1.6	0.881	14.4±2.1	14.7±2.1	0.619	14.4±3.0	15.2±1.4	0.238
Platelets (10^5/ul)	2.3±0.7	2.5±1.3	0.563	2.5±0.9	2.4±0.5	0.529	2.9±1.6	2.8±2.3	0.849

GOT, glutamic oxaloacetic transaminase; GPT, glutamic pyruvic transaminase; BUN, blood urea nitrogen; WBC, white blood cell.
[a]P values for the difference before and after drug treatment.